JP2016506727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506727A5 JP2016506727A5 JP2015555429A JP2015555429A JP2016506727A5 JP 2016506727 A5 JP2016506727 A5 JP 2016506727A5 JP 2015555429 A JP2015555429 A JP 2015555429A JP 2015555429 A JP2015555429 A JP 2015555429A JP 2016506727 A5 JP2016506727 A5 JP 2016506727A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- isolated
- composition
- cbs
- cbs polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 5
- 102100034976 Cystathionine beta-synthase Human genes 0.000 claims 4
- 108010073644 Cystathionine beta-synthase Proteins 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 3
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 claims 3
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 claims 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 229960001570 ademetionine Drugs 0.000 claims 3
- 229960003237 betaine Drugs 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- -1 monohydrazide Chemical compound 0.000 claims 3
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 229960005238 anethole trithione Drugs 0.000 claims 2
- 239000007928 intraperitoneal injection Substances 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- UUWXGCVHZLVCMZ-UHFFFAOYSA-N (4-bromophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C(Br)C=C1 UUWXGCVHZLVCMZ-UHFFFAOYSA-N 0.000 claims 1
- ISZJQQWIYSBXLV-UHFFFAOYSA-N (4-chlorophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C(Cl)C=C1 ISZJQQWIYSBXLV-UHFFFAOYSA-N 0.000 claims 1
- DSLFVZADOTYKJA-UHFFFAOYSA-N (4-fluorophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C(F)C=C1 DSLFVZADOTYKJA-UHFFFAOYSA-N 0.000 claims 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 claims 1
- WGJCBBASTRWVJL-UHFFFAOYSA-N 1,3-thiazolidine-2-thione Chemical compound SC1=NCCS1 WGJCBBASTRWVJL-UHFFFAOYSA-N 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758138P | 2013-01-29 | 2013-01-29 | |
| US61/758,138 | 2013-01-29 | ||
| US13/803,804 | 2013-03-14 | ||
| US13/803,804 US9034318B2 (en) | 2011-08-30 | 2013-03-14 | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| PCT/US2014/013602 WO2014120770A1 (en) | 2013-01-29 | 2014-01-29 | Cystathionine beta-synthase enzyme for treatment of homocystinuria |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018232350A Division JP2019059768A (ja) | 2013-01-29 | 2018-12-12 | ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506727A JP2016506727A (ja) | 2016-03-07 |
| JP2016506727A5 true JP2016506727A5 (enExample) | 2017-04-13 |
| JP6453243B2 JP6453243B2 (ja) | 2019-01-16 |
Family
ID=51223166
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555429A Active JP6453243B2 (ja) | 2013-01-29 | 2014-01-29 | ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 |
| JP2018232350A Withdrawn JP2019059768A (ja) | 2013-01-29 | 2018-12-12 | ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 |
| JP2020169596A Active JP7240743B2 (ja) | 2013-01-29 | 2020-10-07 | ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素 |
| JP2023028266A Active JP7580822B2 (ja) | 2013-01-29 | 2023-02-27 | ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018232350A Withdrawn JP2019059768A (ja) | 2013-01-29 | 2018-12-12 | ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 |
| JP2020169596A Active JP7240743B2 (ja) | 2013-01-29 | 2020-10-07 | ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素 |
| JP2023028266A Active JP7580822B2 (ja) | 2013-01-29 | 2023-02-27 | ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9034318B2 (enExample) |
| EP (4) | EP4406536A3 (enExample) |
| JP (4) | JP6453243B2 (enExample) |
| CN (2) | CN112574982B (enExample) |
| AU (3) | AU2014212471B2 (enExample) |
| BR (1) | BR112015017775A2 (enExample) |
| DK (1) | DK3712264T5 (enExample) |
| FI (1) | FI3712264T3 (enExample) |
| HK (1) | HK1213291A1 (enExample) |
| IL (1) | IL239783B (enExample) |
| PT (1) | PT3712264T (enExample) |
| WO (1) | WO2014120770A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003251550A1 (en) | 2002-06-17 | 2003-12-31 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| US9034318B2 (en) * | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| EP3415489A1 (en) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| ES2994256T3 (en) | 2015-11-09 | 2025-01-21 | Univ Colorado Regents | Compositions and methods for treatment of homocystinuria |
| CA3059592A1 (en) | 2017-04-17 | 2018-10-25 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
| CN110603324A (zh) | 2017-05-12 | 2019-12-20 | 得克萨斯大学体系董事会 | 用于治疗高同型半胱氨酸血症和同型胱胺酸尿症患者的人类酶介导的同型半胱氨酸耗竭 |
| US20190309271A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating homocystinuria |
| CN108795913B (zh) * | 2018-05-04 | 2021-07-02 | 山西大学 | 一种植物中能催化h2s产生的酶及其应用 |
| CN113260324A (zh) | 2018-10-26 | 2021-08-13 | 得克萨斯大学体系董事会 | 用于治疗用途的工程化灵长目动物胱氨酸/半胱氨酸降酶 |
| EP3990005B1 (en) | 2019-06-26 | 2025-08-27 | Travere Therapeutics Switzerland GmbH | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria |
| CA3152379A1 (en) * | 2019-09-03 | 2021-03-11 | Travere Therapeutics Switzerland Gmbh | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels |
| USD1013704S1 (en) * | 2021-07-09 | 2024-02-06 | The Regents Of The University Of Colorado, A Body Corporate | Display screen or portion thereof with graphical user interface |
| USD1014518S1 (en) * | 2021-07-09 | 2024-02-13 | The Regents Of The University Of Colorado, A Body Corporate | Display screen or portion thereof with graphical user interface |
| CN115721735A (zh) * | 2022-10-13 | 2023-03-03 | 呈诺再生医学科技(北京)有限公司 | Cbs基因在制备糖尿病视网膜病变治疗药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57209206A (en) | 1981-06-08 | 1982-12-22 | Kanebo Ltd | Skin type pack agent |
| US5523225A (en) | 1993-09-13 | 1996-06-04 | Regents Of The University Of Colorado | DNA sequence encoding human cystathionine β-synthase |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5635375A (en) | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6635438B2 (en) * | 1999-11-02 | 2003-10-21 | Catch, Inc. | Enzymatic cycling assays for homocysteine and cystathionine |
| AU2003251550A1 (en) * | 2002-06-17 | 2003-12-31 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| EP1396537A1 (en) | 2002-09-04 | 2004-03-10 | Avidis SA | Treatment of elevated plasma homocysteine |
| CN101322840A (zh) * | 2008-05-28 | 2008-12-17 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 一种人胱硫醚β-合成酶重组蛋白及应用 |
| US9364497B2 (en) | 2010-07-01 | 2016-06-14 | Isis Innovation Limited | Treatment of cognitive disorders |
| US9034318B2 (en) * | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9243239B2 (en) | 2012-03-26 | 2016-01-26 | The Regents Of The University Of Colorado, A Body Corporate | Purification of cystathionine beta-synthase |
| US9675678B2 (en) * | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
-
2013
- 2013-03-14 US US13/803,804 patent/US9034318B2/en active Active
-
2014
- 2014-01-29 EP EP24168742.5A patent/EP4406536A3/en active Pending
- 2014-01-29 PT PT201682077T patent/PT3712264T/pt unknown
- 2014-01-29 CN CN202011103747.1A patent/CN112574982B/zh active Active
- 2014-01-29 HK HK16101148.1A patent/HK1213291A1/zh unknown
- 2014-01-29 EP EP17172478.4A patent/EP3282013B1/en active Active
- 2014-01-29 JP JP2015555429A patent/JP6453243B2/ja active Active
- 2014-01-29 AU AU2014212471A patent/AU2014212471B2/en active Active
- 2014-01-29 EP EP14705634.5A patent/EP2951299B1/en active Active
- 2014-01-29 DK DK20168207.7T patent/DK3712264T5/da active
- 2014-01-29 EP EP20168207.7A patent/EP3712264B1/en active Active
- 2014-01-29 FI FIEP20168207.7T patent/FI3712264T3/fi active
- 2014-01-29 WO PCT/US2014/013602 patent/WO2014120770A1/en not_active Ceased
- 2014-01-29 BR BR112015017775A patent/BR112015017775A2/pt not_active Application Discontinuation
- 2014-01-29 CN CN201480006554.0A patent/CN105452457A/zh active Pending
-
2015
- 2015-04-15 US US14/687,389 patent/US9447406B2/en active Active
- 2015-07-05 IL IL23978315A patent/IL239783B/en active IP Right Grant
-
2016
- 2016-08-12 US US15/235,355 patent/US10046036B2/en active Active
-
2018
- 2018-07-02 US US16/025,652 patent/US10624959B2/en active Active
- 2018-12-12 JP JP2018232350A patent/JP2019059768A/ja not_active Withdrawn
-
2020
- 2020-01-31 AU AU2020200719A patent/AU2020200719B2/en active Active
- 2020-10-07 JP JP2020169596A patent/JP7240743B2/ja active Active
-
2022
- 2022-11-04 AU AU2022263598A patent/AU2022263598B2/en active Active
-
2023
- 2023-02-27 JP JP2023028266A patent/JP7580822B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506727A5 (enExample) | ||
| FI3712264T3 (fi) | Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon | |
| JP2019194251A5 (enExample) | ||
| JP2017528444A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| AR065349A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| RU2010114018A (ru) | Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства | |
| CO6331292A2 (es) | Compuestos de insulina lispro pegilada | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| BRPI1014416B1 (pt) | Nova variante de exendina e conjugado desta | |
| JP2016535020A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| CA2846598C (en) | Treatment of degenerative joint disease | |
| RU2020121540A (ru) | Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта | |
| JP2017533201A5 (enExample) | ||
| RU2015110114A (ru) | Ангиотензин в лечении состояний головного мозга | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| SA521431197B1 (ar) | منتج دوائي للعلاج بالإنزيم لعلاج البيلة الهوموسيستينية (اضطراب في الهوموسيستين) | |
| JP2016530284A5 (enExample) | ||
| JP2020520677A5 (enExample) | ||
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EP4487914A2 (en) | Compositions and methods for treatment of homocystinuria |